Shares of Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $151.01 and traded as high as $162.61. Twist Bioscience shares last traded at $159.85, with a volume of 1,755,741 shares traded.
Analyst Upgrades and Downgrades
TWST has been the subject of a number of recent analyst reports. Robert W. Baird lifted their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Canaccord Genuity Group upped their price objective on shares of Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, October 12th. BWS Financial restated a “sell” rating and issued a $45.00 price objective on shares of Twist Bioscience in a report on Friday, September 18th. Guggenheim increased their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Leerink Partners lifted their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $143.67.
View Our Latest Report on TWST
Twist Bioscience Stock Up 10.1%
The company has a fifty day moving average of $151.01 and a 200-day moving average of $86.87.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same period last year, the business earned $0.33 EPS. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Insider Activity at Twist Bioscience
In related news, CAO Robert F. Werner sold 1,482 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $279,920.16. Following the completion of the transaction, the chief accounting officer owned 42,917 shares in the company, valued at approximately $8,106,162.96. The trade was a 3.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 4,548 shares of Twist Bioscience stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $202.15, for a total transaction of $919,378.20. Following the completion of the transaction, the chief executive officer owned 562,760 shares of the company’s stock, valued at $113,761,934. This trade represents a 0.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 601,920 shares of company stock valued at $93,768,202. 3.08% of the stock is owned by company insiders.
Institutional Investors Weigh In On Twist Bioscience
A number of hedge funds have recently added to or reduced their stakes in TWST. BlackRock Inc. acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $600,191,000. William Blair Investment Management LLC acquired a new position in shares of Twist Bioscience in the second quarter worth $223,722,000. Bank of America Corp DE acquired a new position in shares of Twist Bioscience in the second quarter worth $94,922,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Twist Bioscience in the first quarter worth $22,563,000. Finally, Sei Investments Co. increased its position in shares of Twist Bioscience by 31.2% during the first quarter. Sei Investments Co. now owns 354,420 shares of the company’s stock worth $16,842,000 after acquiring an additional 84,321 shares during the period.
About Twist Bioscience
Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.
Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.
Featured Stories
- Five stocks we like better than Twist Bioscience
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
